Chronic nonhealing wounds represent a large clinical problem resulting in s
evere disabilities and large healthcare expenditures. Despite the scope of
this problem, effective new therapies are lacking. The deficiency of growth
factors in chronic wounds has brought attention to the topical application
of growth factors, but initial clinical trials have resulted in only modes
t improvements in healing despite large, repetitive doses. The modest impro
vement in healing observed in these trials show that growth factors can imp
rove chronic wound healing, but a better means of growth factor delivery is
needed. We hypothesized that gene therapy using a recombinant adenoviral v
ector could be used to induce transgene production directly by cells in the
wound. An adenovirus containing the beta-galactosidase reporter transgene
(Ad-LacZ) was used in the ischemic rabbit ear model to test this hypothesis
. Ad-LacZ resulted in efficient transgene delivery to cells participating i
n the wound healing response, with expression up to 2 weeks. However, wound
reepithelialization was impaired in Ad-LacZ treated wounds compared to veh
icle control wounds, Adenoviral mediated gene transfer is a promising effic
ient means of growth factor delivery to chronic wounds. However, selection
of the proper transgene with appropriate biologic activity in wound healing
may be essential to overcome the potential adverse effects of adenoviral i
nfection.